Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
January 10, 2025 07:00 ET
|
Arvinas Inc.
– Vepdegestrant to be combined with Pfizer’s novel investigational CDK4 inhibitor atirmociclib in a first-line Phase 3 trial planned to initiate in 2025; a second-line Phase 3 combination trial will...
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
January 10, 2025 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Targeted Protein Degradation Industry Forecast to Reach $4.37 Billion by 2034: PROTACs Lead the Charge with Promising Innovations in Oncology
December 20, 2024 07:12 ET
|
Research and Markets
Dublin, Dec. 20, 2024 (GLOBE NEWSWIRE) -- The "Global Targeted Protein Degradation Market by Type, by Application, by End-User, and by Region" report has been added to ResearchAndMarkets.com's...
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
December 13, 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
Targeted Protein Degradation Market Research, 2018-2030: Size, Share & Trends Analysis by Type, Application, End-use and Region
December 11, 2024 04:21 ET
|
Research and Markets
Dublin, Dec. 11, 2024 (GLOBE NEWSWIRE) -- The "Targeted Protein Degradation Market Size, Share & Trends Analysis by Type (PROTAC, LYTACs), Application (Drug Discovery), End Use (Hospitals,...
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
December 10, 2024 09:05 ET
|
Arvinas Inc.
– Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate: 62.5%; overall response rate: 26.7%) in patients previously treated with a CDK4/6...
Targeted Protein Degradation Market Growing at 20.7% CAGR to Hit USD 3547.91 million by 2034 | PMR
December 09, 2024 06:35 ET
|
Polaris Market Research & Consulting LLP
New York, USA, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Market Overview The global targeted protein degradation market size is projected to grow from USD 541.98 million in 2024 to USD 3547.91 million by...
Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference
November 27, 2024 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium
November 25, 2024 17:35 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that three posters for vepdegestrant, including clinical data, will be presented at the 2024 San...